Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens

Sponsor
Fujian Cancer Hospital
Study ID
NCT04089657
Phase
PHASE2
Status
Unknown

Conditions

  • Advanced Metastatic Gastric Cancer

Eligibility Criteria

Sex
ALL
Age
20 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib Mesylate — DRUG
    Apatinib 500mg qd, oral, taken half an hour after a meal
  • Sintilimab — DRUG
    Sintilimab 200mg intravenously on day 1

Study Details

The purpose of this study is to assess the efficacy and safety of Apatinib combined with PD-1 antibody Sintilimab for for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer

Key Dates

Start date
Dec 1, 2019
Status verified
Sep 2019
Primary completion
Dec 1, 2020
Completion
Dec 1, 2021

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib+Sintilimab
    Apatinib 500mg qd p.o and Sintilimab 200mg intravenously on day 1 every 3 weeks until disease progression or intolerable toxicity or patients withdrawal of consent

Primary Outcome Measure

Disease control rate(DCR) [ Time Frame: 12 months ]

Central Contacts